Expertise in
14
conditions

Virginie Gandemer

Rennes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
Rennes, FR 
OverviewLocationsClinical Research

Overview

Virginie Gandemer practices in Rennes, France. Ms. Gandemer is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, RUNX1 Familial Platelet Disorder, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 172 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Rennes, France
Other Locations
Nantes, France
Marseille, France
Poitiers, 86000, France
CHU Bordeaux
Bordeaux, France
Montpellier, France
Paris, France
Angers, France
Saint-jean-saint-germain, France
Limoges, France
Lille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
Enrollment Status: Completed
Publish Date: August 29, 2022
Intervention Type: Drug
Study Drugs: Velbe+Bleomycin+Cisplatin, Vepeside+Ifosfamide+Cisplatin
Study Phase: Phase 2
Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
Enrollment Status: Completed
Publish Date: April 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

172 Total Publications

Prevention and management of heavy uterine bleeding in pediatric patients treated for an acute leukemia: Guidelines of the SFCE leukemia committee
Prevention and management of heavy uterine bleeding in pediatric patients treated for an acute leukemia: Guidelines of the SFCE leukemia committee
Journal: Bulletin du cancer
Published: March 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gandemer's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile